Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Patel Sanj K	2. Issuer Name and Ticker or Trading Symbol Kiniksa Pharmaceuticals, Ltd. [ KNSA ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chairman & CEO
(Last) (First) (Middle) C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE 2 CHURCH STREET	3. Date of Earliest Transaction (MM/DD/YYYY) 10/9/2020
(Street) HAMILTON, D0 HM11 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Shares	10/9/2020		M⁽¹⁾		872	A	$1.59	872	D
Class A Common Shares	10/9/2020		S⁽¹⁾		872	D	$21.00 ⁽²⁾	0	D
Class A Common Shares	10/9/2020		S⁽¹⁾		670	D	$21	211900	I	Held by the Anglia 2013 Revocable Trust, u/d/t August 15, 2013
Class A Common Shares	10/12/2020		M⁽¹⁾		150700	A	$1.59	150700	D
Class A Common Shares	10/12/2020		S⁽¹⁾		150700	D	$21.02 ⁽³⁾	0	D
Class A Common Shares	10/12/2020		S⁽¹⁾		99330	D	$21.02 ⁽³⁾	112570	I	Held by the Anglia 2013 Revocable Trust, u/d/t August 15, 2013
Class A Common Shares								109795	I	Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option	$1.59	10/9/2020		M ⁽¹⁾			872	⁽⁴⁾	12/15/2025	Class A Common Shares	872	$0	502896	D
Share Option	$1.59	10/12/2020		M ⁽¹⁾			150700	⁽⁴⁾	12/15/2025	Class A Common Shares	150700	$0	352196	D

Explanation of Responses:
(1)	The sale of Class A Common Shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person.
(2)	This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.00 to $21.01. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
(3)	This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.00 to $21.08. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
(4)	The option is fully vested and exercisable.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Patel Sanj K C/O KINIKSA PHARMACEUTICALS, LTD. CLARENDON HOUSE 2 CHURCH STREET HAMILTON, D0 HM11	X		Chairman & CEO